The role of add-back therapy in the United States.

Drugs of today (Barcelona, Spain : 1998) · 2005 · vol. 41 Suppl A , pp. 23–6 · PMID:16200222 · W3026355599
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-06-07

Add-back therapy with progestin or progestin plus estrogen mitigates hypoestrogenic side effects of GnRH agonists for endometriosis without reducing efficacy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Gonadotropin-releasing hormone (GnRH) agonists are effective in reducing pelvic pain due to endometriosis, but they are associated with a number of hypoestrogenic side effects, such as vasomotor symptoms and loss of bone mineral density. Add-back therapy with a progestin or a progestin plus low-dose estrogen helps to reduce the side effects associated with GnRH agonist administration without compromising efficacy. Add-back therapy should be initiated at the same time as the treatment with a GnRH agonist and longer-term therapy beyond 6 months can be considered in patients meeting the appropriate criteria.

My notes (saved in your browser only)

Condition tags

endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Pelvic Pain Endometriosis Endometriosis Estrogens Estrogens Female Gonadotropin-Releasing Hormone Humans Pelvic Pain Pelvic Pain Progestins Progestins United States

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (7)

Source provenance

europepmc
last seen: 2026-08-15T06:15:18.721777+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:15:29.922408+00:00
License: CC0 · commercial use OK